ATR Inhibitors and Paclitaxel in Melanoma

被引：8

作者：

Ashworth, Alan ^{[1
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94158 USA

来源：

CLINICAL CANCER RESEARCH | 2021年 / 27卷 / 17期

关键词：

D O I：

10.1158/1078-0432.CCR-21-1778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase I study defined a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel and responses were seen in patients with melanoma who had progressed on an immune check-point inhibitor. This combination warrants further exploration to determine the extent and molecular determinants of clinical activity.

引用

页码：4667 / 4668

页数：2

共 6 条

[1] The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia [J].

Bastian, Boris C. .

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 :239-271

[2] A potent Chkl inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress [J].

Brooks, K. ;

Oakes, V. ;

Edwards, B. ;

Ranall, M. ;

Leo, P. ;

Pavey, S. ;

Pinder, A. ;

Beamish, H. ;

Mukhopadhyay, P. ;

Lambie, D. ;

Gabrielli, B. .

ONCOGENE, 2013, 32 (06) :788-796

[3] A mitosis-specific and R loop-driven ATR pathway promotes faithful chromosome segregation [J].

Kabeche, Lilian ;

Nguyen, Hai Dang ;

Buisson, Remi ;

Zou, Lee .

SCIENCE, 2018, 359 (6371) :108-113

[4] Molecular Pathways: Targeting ATR in Cancer Therapy [J].

Karnitz, Larry M. ;

Zou, Lee .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4780-4785

[5] Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer [J].

Kim, Seung Tae ;

Smith, Simon A. ;

Mortimer, Peter ;

Loembe, Arsene-Bienvenu ;

Cho, Heejin ;

Kim, Kyoung-Mee ;

Smith, Claire ;

Willis, Sophie ;

Irurzun-Arana, Itziar ;

Berges, Alienor ;

Hong, Jung Yong ;

Park, Se Hoon ;

Park, Joon Oh ;

Park, Young Suk ;

Lim, Ho Yeong ;

Kang, Won Ki ;

Kozarewa, Iwanka ;

Pierce, Andrew J. ;

Dean, Emma ;

Lee, Jeeyun .

CLINICAL CANCER RESEARCH, 2021, 27 (17) :4700-4709

[6] PARP inhibitors: Synthetic lethality in the clinic [J].

Lord, Christopher J. ;

Ashworth, Alan .

SCIENCE, 2017, 355 (6330) :1152-1158

← 1 →